Clinical Trials Logo

Clinical Trial Summary

Some breast cancer cells make a protein called Human Epidermal Growth factor receptor 2 (HER2). Patients with HER2 positive (HER2+) breast cancer receive medicine that attacks HER2, which helps these patients live longer. Some HER2 negative (HER2-) breast cancer patients also benefit from medicines that attack HER2, but we do not know why or which patients will benefit. This study uses a new imaging method, HER2-targeted PET/CT, to identify patients that may benefit from medicines that attack HER2. This is experimental.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02286843
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Completed
Phase N/A
Start date November 6, 2014
Completion date June 30, 2020